ArticleScientific reports2025
A retrospective study on unfavorable 28-day neurological outcomes of stage II TB meningitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tuberculous meningitis (TBM) is often associated with adverse neurological outcomes, however, there is a lack of relevant research. The aim of this study is to explore the risk factors that affect the poor prognosis of 28-day neurological function in patients with stage II TBM. A retrospective analysis was conducted on the clinical data of patients with stage II TBM who visited our hospital from January 1st, 2018 to August 1st, 2019 based on the staging criteria of the Medical Research Council. The neurological function prognosis after 28 days of follow-up was determined to establish independent risk factors. A total of 138 patients (82 male and 56 female) were included, with an average onset age of 37.01 ± 17.30 years. Forty patients had poor prognosis (Modified Rankin Scale [MRS] score, 3-6 points), while 98 patients had a good prognosis (MRS score, 0-2 points). Multivariate logistic regression analysis showed that peripheral nerve dysfunction (odds ratio [OR], 6.315; 95% confidence interval [CI] 2.319-17.196; p < 0.001), Quick Sequential Organ Failure Assessment (QSOFA) score (OR 7.343; 95% CI 2.984-18.066; p < 0.001), and hydrocephalus (OR 2.685; 95% CI 1.020-7.068; p = 0.045) were independent risk factors. The area under the curve for predicting the 28-day neurological prognosis of patients with stage II TBM using the QSOFA score was 0.766 (95% CI 0.680-0.853; p < 0.001). Peripheral nerve dysfunction, QSOFA score, and hydrocephalus are independent risk factors for 28-day neurological dysfunction in patients with stage II TBM. The QSOFA score had good predictive ability of the prognosis in terms of 28-day neurological function of patients with stage II TBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.